Class information for:
Level 1: 5 ALPHA REDUCTASE//FINASTERIDE//BIOL SYST ANIM PROD

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
6989 1343 30.8 66%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
157 21931 BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 5 ALPHA REDUCTASE Author keyword 48 30% 10% 132
2 FINASTERIDE Author keyword 40 24% 11% 145
3 BIOL SYST ANIM PROD Address 35 89% 1% 16
4 5 ALPHA REDUCTASE INHIBITOR Author keyword 23 36% 4% 52
5 DUTASTERIDE Author keyword 18 27% 4% 56
6 5 ALPHA REDUCTION Author keyword 18 89% 1% 8
7 SRD5A2 GENE Author keyword 16 65% 1% 15
8 5 ALPHA REDUCTASE DEFICIENCY Author keyword 15 56% 1% 18
9 5 ALPHA REDUCTASE INHIBITORS Author keyword 14 27% 3% 43
10 FLANK ORGANS Author keyword 14 100% 1% 7

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 5 ALPHA REDUCTASE 48 30% 10% 132 Search 5+ALPHA+REDUCTASE Search 5+ALPHA+REDUCTASE
2 FINASTERIDE 40 24% 11% 145 Search FINASTERIDE Search FINASTERIDE
3 5 ALPHA REDUCTASE INHIBITOR 23 36% 4% 52 Search 5+ALPHA+REDUCTASE+INHIBITOR Search 5+ALPHA+REDUCTASE+INHIBITOR
4 DUTASTERIDE 18 27% 4% 56 Search DUTASTERIDE Search DUTASTERIDE
5 5 ALPHA REDUCTION 18 89% 1% 8 Search 5+ALPHA+REDUCTION Search 5+ALPHA+REDUCTION
6 SRD5A2 GENE 16 65% 1% 15 Search SRD5A2+GENE Search SRD5A2+GENE
7 5 ALPHA REDUCTASE DEFICIENCY 15 56% 1% 18 Search 5+ALPHA+REDUCTASE+DEFICIENCY Search 5+ALPHA+REDUCTASE+DEFICIENCY
8 5 ALPHA REDUCTASE INHIBITORS 14 27% 3% 43 Search 5+ALPHA+REDUCTASE+INHIBITORS Search 5+ALPHA+REDUCTASE+INHIBITORS
9 FLANK ORGANS 14 100% 1% 7 Search FLANK+ORGANS Search FLANK+ORGANS
10 4 AZASTEROIDS 11 100% 0% 6 Search 4+AZASTEROIDS Search 4+AZASTEROIDS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 STEROID 5 ALPHA REDUCTASE 69 33% 13% 171
2 HUMAN STEROID 5 ALPHA REDUCTASE 63 67% 4% 56
3 FINASTERIDE 60 19% 21% 278
4 MALE PSEUDOHERMAPHRODITISM 58 30% 12% 162
5 5ALPHA REDUCTASE DEFICIENCY 47 86% 2% 24
6 DIHYDROTESTOSTERONE 30 19% 10% 139
7 MK 906 28 81% 1% 17
8 AZASTEROIDS 28 53% 3% 37
9 FINASTERIDE MK 906 24 91% 1% 10
10 3 ANDROSTENE 3 CARBOXYLIC ACIDS 23 86% 1% 12

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
STEROID 5-ALPHA-REDUCTASE - 2 GENES 2 ENZYMES 1994 655 80 66%
An overview on 5 alpha-reductase inhibitors 2010 65 169 68%
The rationale for inhibiting 5 alpha-reductase isoenzymes in the prevention and treatment of prostate cancer 2008 60 42 67%
Type 1 and type 2 5 alpha-reductase expression in the development and progression of prostate cancer 2008 55 51 67%
A tale of two trials: The impact of 5 alpha-reductase inhibition on prostate cancer 2014 2 28 50%
FINASTERIDE 1994 212 54 65%
Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia 2002 57 90 52%
Use of 5-alpha-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline 2009 47 45 38%
Discovery and clinical development of dutasteride, a potent dual 5 alpha-reductase inhibitor 2006 31 69 77%
Role of 5 alpha-Reductase Inhibitors in Prostate Cancer Prevention and Treatment 2012 11 54 43%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOL SYST ANIM PROD 35 89% 1.2% 16
2 DIABET ENDOCRINE METAB PEDIAT UNIT 3 100% 0.2% 3
3 BIOESTRUCTURA 2 38% 0.4% 5
4 UROL CLIN DEV MED AFFAIRS 2 67% 0.1% 2
5 UNIDAD INVEST ENDOCRINOL NUTR PEDIAT 2 50% 0.2% 3
6 COMPOSTI ETEROCICLICI CNR 1 100% 0.1% 2
7 MED NEW YORK HOSP ENDOCRINOL METAB 1 100% 0.1% 2
8 PEDIATMED GENET CLIN 1 50% 0.1% 2
9 UNITA ENDOCRINOL 1 14% 0.5% 7
10 HOP LA MIL 1 40% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000157784 FOSFESTROL//IDIOPATHIC URETHRITIS//5 ALPHA ANDROSTANEDIOL
2 0.0000147800 D 004//PC SPES//SERENOA REPENS
3 0.0000130328 PEROPERATIVE BLEEDING//PRIMARY PROSTATE CULTURE//BLOOD VESSEL MORPHOLOGY
4 0.0000108524 LOWER URINARY TRACT SYMPTOMS//BENIGN PROSTATIC HYPERPLASIA//LUTS
5 0.0000083830 17 BETA HYDROXYSTEROID DEHYDROGENASE//17 BETA HSD2//17 BETA HSD1
6 0.0000082177 TZP 4238//CHLORMADINONE ACETATE CMA//PREVENTION OF ESTRUS
7 0.0000081557 ANDROGENETIC ALOPECIA//FEMALE PATTERN HAIR LOSS//MALE PATTERN HAIR LOSS
8 0.0000080393 PROSTATE DEVELOPMENT//BIOL SCI VET MED//PROSTATE STEM CELL
9 0.0000074206 HIRSUTISM//IDIOPATHIC HIRSUTISM//3 ALPHA ANDROSTANEDIOL GLUCURONIDE
10 0.0000068592 HYPOSPADIAS//STUDY TREATMENT HYPOSPADIAS//GENITAL TUBERCLE